Clinical trial
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
NCT01376258 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
- Lead sponsor
- GlaxoSmithKline
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- December 31, 2010
- Enrollment
- 28,903 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.